{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T23:40:26Z","timestamp":1720395626458},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurg"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00104-018-0679-1","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T08:10:41Z","timestamp":1530778241000},"page":"678-686","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chirurgische Therapie bei peritonealen Metastasen gyn\u00e4kologischer Prim\u00e4rtumoren","Surgical treatment of peritoneal metastases from gynecological primary tumors"],"prefix":"10.1007","volume":"89","author":[{"given":"P.","family":"Horvath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,5]]},"reference":[{"key":"679_CR1","unstructured":"S3 Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumore. https:\/\/www.ago-online.de\/fileadmin\/downloads\/leitlinien\/ovar\/2016\/032-035-OLk_Ovarialkarzinom_2016-10.pdf"},{"key":"679_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ejso.2006.03.011","volume":"32","author":"F Raspagliesi","year":"2006","unstructured":"Raspagliesi F, Kusamura S, Campos Torres JC et\u00a0al (2006) Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced\/recurrent ovarian caner patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 32:671\u2013675","journal-title":"Eur. J. Surg. Oncol."},{"key":"679_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF et\u00a0al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N\u00a0Engl J Med 334:1\u20136","journal-title":"N Engl J Med"},{"issue":"12","key":"679_CR4","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00104-007-1431-4","volume":"78","author":"J Pfisterer","year":"2007","unstructured":"Pfisterer J, Harter P, Hilpert F et\u00a0al (2007) Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results. Chirurg 78(12):1111\u20131116","journal-title":"Chirurg"},{"issue":"5","key":"679_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a\u00a0meta-analysis. J\u00a0Clin Oncol 20(5):1248\u20131259","journal-title":"J Clin Oncol"},{"issue":"2","key":"679_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ygyno.2015.12.007","volume":"140","author":"B Ataseven","year":"2016","unstructured":"Ataseven B, Grimm C, Harter P et\u00a0al (2016) Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecol Oncol 140(2):215\u2013220","journal-title":"Gynecol Oncol"},{"key":"679_CR7","unstructured":"Wimberger P, Lehmann N, Kimmig R et al (2007) Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a\u00a0prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Gynecol Oncol 106(1):69\u201374"},{"key":"679_CR8","first-page":"446","volume":"26","author":"J Pfisterer","year":"2003","unstructured":"Pfisterer J, Hilpert F, du Bois A et al (2003) State-of-the-art first-line treatment of ovarian cancer. Onkologie 26:446\u2013450","journal-title":"Onkologie"},{"key":"679_CR9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s001290101112","volume":"34","author":"A DuBois","year":"2001","unstructured":"DuBois A, Pfisterer J, Kellermann L (2001) Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland. Gyn\u00e4kologe 34:1029\u20131040","journal-title":"Gyn\u00e4kologe"},{"issue":"38","key":"679_CR10","first-page":"635","volume":"108","author":"A Burges","year":"2011","unstructured":"Burges A, Schmalfeldt B (2011) Ovarian cancer: diagnosis and treatment. Dtsch Arztebl Int 108(38):635\u2013641","journal-title":"Dtsch Arztebl Int"},{"issue":"10","key":"679_CR11","doi-asserted-by":"publisher","first-page":"e0186725","DOI":"10.1371\/journal.pone.0186725","volume":"12","author":"L Yang","year":"2017","unstructured":"Yang L, Zhang B, Xing G et al (2017) Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: a meta-analysis of peri-operative outcome. PLoS ONE 12(10):e186725. https:\/\/doi.org\/10.1371\/journal.pone.0186725","journal-title":"PLoS ONE"},{"issue":"9","key":"679_CR12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1097\/IGC.0000000000001108","volume":"27","author":"G Bogani","year":"2017","unstructured":"Bogani G, Matteucci L, Tamberi S et al (2017) The impact of number of cycles of neoadjuvant chemotherapy on survival of patients undergoing interval debulking surgery for stage IIIC-IV unresectable ovarian cancer: results from a\u00a0multi-institutional study. Int J Gynecol Cancer 27(9):1856\u20131862","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"679_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","volume":"112","author":"RE Bristow","year":"2009","unstructured":"Bristow RE, Puri I, Chi DS (2009) Cytoreductive surgery for recurrent ovarian cancer: a\u00a0meta-analysis. Gynecol Oncol 112(1):265\u2013274","journal-title":"Gynecol Oncol"},{"issue":"Suppl_15","key":"679_CR14","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","volume":"30","author":"A Bois Du","year":"2017","unstructured":"Du Bois A, Vergote I, Ferron G et\u00a0al (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J\u00a0Clin Oncol 30(Suppl_15):5501. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.5501","journal-title":"J Clin Oncol"},{"issue":"5","key":"679_CR15","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1245\/s10434-009-0357-0","volume":"16","author":"P Harter","year":"2009","unstructured":"Harter P, Hahmann M, Lueck HJ et\u00a0al (2009) Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16(5):1324\u20131330","journal-title":"Ann Surg Oncol"},{"key":"679_CR16","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1245\/s10434-012-2510-4","volume":"19","author":"M Bakrin","year":"2012","unstructured":"Bakrin M, Cotte E, Golfier F et\u00a0al (2012) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: A multicenter, prospective study of 246 patients. Ann Surg Oncol 19:4052\u20134058","journal-title":"Ann Surg Oncol"},{"key":"679_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1006\/gyno.1993.1081","volume":"49","author":"K Bertelsen","year":"1993","unstructured":"Bertelsen K, Jakobsen A, Stroyer J et\u00a0al (1993) A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a\u00a0Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 49:30\u201336","journal-title":"Gynecol Oncol"},{"key":"679_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/1096-9098(200009)75:1<24::AID-JSO5>3.0.CO;2-L","volume":"75","author":"RY Zang","year":"2000","unstructured":"Zang RY, Zhang ZY, Li ZT et\u00a0al (2000) Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J\u00a0Surg Oncol 75:24\u201330","journal-title":"J Surg Oncol"},{"key":"679_CR19","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s00268-004-7461-x","volume":"28","author":"C Zanon","year":"2004","unstructured":"Zanon C, Clara R, Chiappino I et\u00a0al (2004) Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis of ovarian cancer. World J Surg 28:1040\u20131045","journal-title":"World J Surg"},{"issue":"29","key":"679_CR20","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J\u00a0Clin Oncol 24(29):4699\u20134707","journal-title":"J Clin Oncol"},{"issue":"4","key":"679_CR21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/bjc.2012.307","volume":"107","author":"I Vergote","year":"2012","unstructured":"Vergote I, Piccirillo MC, Fossati R et al (2012) Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107(4):588\u2013591","journal-title":"Br J Cancer"},{"issue":"14","key":"679_CR22","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et\u00a0al (2001) Recurrent epithelial ovarian carcinoma: a\u00a0randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J\u00a0Clin Oncol 19(14):3312\u20133312","journal-title":"J Clin Oncol"},{"key":"679_CR23","unstructured":"S3 Leitlinie Kolorektales Karzinom. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/021-007OLl_S3_KRK_2017-12_1.pdf . Zugegriffen: 1.\u00a0Novemer 2017"},{"key":"679_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-7819-2-21","volume":"2","author":"P Piso","year":"2004","unstructured":"Piso P, Dahlke MH, Loss M et\u00a0al (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2:21","journal-title":"World J Surg Oncol"},{"key":"679_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/jso.20243","volume":"90","author":"TW Reichman","year":"2005","unstructured":"Reichman TW, Cracchiolo B, Sama J et\u00a0al (2005) Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J\u00a0Surg Oncol 90:51\u201358","journal-title":"J Surg Oncol"},{"issue":"1","key":"679_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ygyno.2006.10.051","volume":"105","author":"CW Helm","year":"2007","unstructured":"Helm CW, Randall-Whitis L, Martin RS 3rd et al (2007) Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 105(1):90\u201396","journal-title":"Gynecol Oncol"},{"key":"679_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","volume":"106","author":"JH Bae","year":"2007","unstructured":"Bae JH, Lee JM, Ryu KS et al (2007) Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 106:193\u2013200","journal-title":"Gynecol Oncol"},{"issue":"9","key":"679_CR28","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00268-007-9146-8","volume":"31","author":"E Cotte","year":"2007","unstructured":"Cotte E, Glehen O, Mohamed F et al (2007) Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31(9):1813\u20131820","journal-title":"World J Surg"},{"issue":"2","key":"679_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cncr.23553","volume":"13","author":"A Giorgio Di","year":"2008","unstructured":"Di Giorgio A, Naticchioni E, Biacchi D et\u00a0al (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 13(2):315\u2013325","journal-title":"Cancer"},{"key":"679_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ygyno.2009.03.004","volume":"113","author":"A Fagotti","year":"2009","unstructured":"Fagotti A, Paris I, Grimolizzi F et al (2009) Secondary cytorecuction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study. Gynecol Oncol 113:335\u2013340","journal-title":"Gynecol Oncol"},{"key":"679_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","volume":"127","author":"A Fagotti","year":"2012","unstructured":"Fagotti A, Costantini B, Petrillo M et al (2012) Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol 127:502\u2013505","journal-title":"Gynecol Oncol"},{"key":"679_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/j.1471-0528.2011.03207.x","volume":"119","author":"M Deraco","year":"2012","unstructured":"Deraco M, Virz\u00ec S, Iusco DR et al (2012) Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a\u00a0multi-institutional study. BJOG 119:800\u2013809","journal-title":"BJOG"},{"key":"679_CR33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ijc.29011","volume":"136","author":"O Zivanovic","year":"2014","unstructured":"Zivanovic O, Abramian A, Kullmann M et al (2014) HIPEC ROC I: a phase-I-study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer 136:699\u2013708","journal-title":"Int J Cancer"},{"key":"679_CR34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00423-014-1207-5","volume":"399","author":"I K\u00f6nigsrainer","year":"2014","unstructured":"K\u00f6nigsrainer I, Horvath P, Struller F et\u00a0al (2014) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a\u00a0single centre experience. Langenbecks Arch Surg 399:589\u2013594","journal-title":"Langenbecks Arch Surg"},{"key":"679_CR35","first-page":"54","volume":"1","author":"F Coccolini","year":"2014","unstructured":"Coccolini F, Campanati L, Catena F et\u00a0al (2014) Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a\u00a0multicenter prospective observational study. J\u00a0Gynecol Oncol 1:54\u201361","journal-title":"J Gynecol Oncol"},{"key":"679_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2016.09.014","volume":"143","author":"JJ Mueller","year":"2016","unstructured":"Mueller JJ, Kelly A, Zhou Q et al (2016) Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: feasibility and outcomes at a\u00a0comprehensive cancer center. Gynecol Oncol 143:496\u2013503","journal-title":"Gynecol Oncol"},{"key":"679_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.tranon.2016.02.002","volume":"9","author":"JH Sun","year":"2016","unstructured":"Sun JH, Zjhong-He J, Yang Y et al (2016) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat advanced\/recurrent epithelial ovarian cancer: results from a\u00a0retrospective study on prospectively established database. Transl Oncol 9:130\u2013138","journal-title":"Transl Oncol"},{"issue":"17","key":"679_CR38","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA et al (2012) OCEANS: a\u00a0randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J\u00a0Clin Oncol 30(17):2039\u20132045","journal-title":"J Clin Oncol"},{"issue":"26","key":"679_CR39","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV et\u00a0al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N\u00a0Engl J Med 335(26):1950\u20131955","journal-title":"N Engl J Med"},{"key":"679_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/gyno.1999.5677","volume":"76","author":"A Gadducci","year":"2000","unstructured":"Gadducci A, Carnino F, Chiara S et al (2000) Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanved epithelial ovarian cancer: a\u00a0randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 76:157\u2013162","journal-title":"Gynecol Oncol"},{"key":"679_CR41","doi-asserted-by":"crossref","unstructured":"Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma. An intergroup study of the Gynecologic Oncology group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 4:1001\u20131007","DOI":"10.1200\/JCO.2001.19.4.1001"},{"key":"679_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"DK Armstrong","year":"2006","unstructured":"Armstrong DK, Bundy B, Wenzel L et\u00a0al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N\u00a0Engl J Med 354:34\u201343","journal-title":"N Engl J Med"},{"key":"679_CR43","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","volume":"33","author":"D Tewari","year":"2015","unstructured":"Tewari D, Java JJ, Salani R et al (2015) Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a\u00a0gynecological oncology group study. J\u00a0Clin Oncol 33:1460\u20131466","journal-title":"J Clin Oncol"},{"key":"679_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ Driel Van","year":"2018","unstructured":"Van Driel WJ, Koole SN, Sikorska K et\u00a0al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N\u00a0Engl J Med 378:230\u2013240","journal-title":"N Engl J Med"},{"key":"679_CR45","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","volume":"22","author":"J Spiliotis","year":"2015","unstructured":"Spiliotis J, Halkia E, Lianos E et\u00a0al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a\u00a0prospective randomized phase III study. Ann Surg Oncol 22:1570\u20131575","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"679_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0020-7292(00)00340-4","volume":"72","author":"MS Yen","year":"2001","unstructured":"Yen MS, Juang CM, Lai CR et al (2001) Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 72(1):55\u201360","journal-title":"Int J Gynaecol Obstet"}],"container-title":["Der Chirurg"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00104-018-0679-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-018-0679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-018-0679-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T23:22:51Z","timestamp":1720394571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00104-018-0679-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,5]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1007\/s00104-018-0679-1","relation":{},"ISSN":["0009-4722","1433-0385"],"issn-type":[{"value":"0009-4722","type":"print"},{"value":"1433-0385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,5]]},"assertion":[{"value":"5 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Horvath und A.\u00a0K\u00f6nigsrainer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}